Barinthus Biotherapeutics plc Sponsored ADR BRNS 深 沪
已收盘 05-15 16:00:00 美东时间
0.6796
-0.031
-4.42%
华盛通- 最 高0.73
- 今 开0.73
- 成交量 1.07万股
- 最 低 0.6369
- 昨 收 0.711
- 总市值 2776.09万
- 52周最高 2.92
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 0.512
- 委 比 99.99%
- 总股本 4084.89万
- 历史最高 17.99
- 量 比 0.42
- 振 幅 13.09%
- 历史最低 0.512
- 每 手 1
- 风险率 0.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Barinthus Biotherapeutics Q1 EPS $(0.14) Beats $(0.30) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 71.43 percent increase over losses of $(0.49) per
04-30 19:59
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Qualcomm shares rose 10.6% in pre-market trading after reporting better-than-expected Q2 results. Other gainers include ABTS, AKAN, VSME, OSRH, AREB, VIAV, PI, INM, and MRAM.
04-30 17:26
Barinthus Biotherapeutics Q4 EPS $(0.27) Beats $(0.40) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.40) by 32.5 percent. This is a 47.06 percent increase over losses of $(0.51) per
03-13 20:07
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 23.3% to $0.16 during Tues...
03-11 05:06
Barinthus Bio Issues Update On First-In-Human Phase 1 Trial Of VTP-1000 In Adults With Celiac Disease
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEsThe MAD portion
2025-12-10 21:01
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and raises the price target from $3 to $4.
2025-11-17 20:29
ChemDiv To Continue R&D Support As Clywedog Merges With Barinthus Therapeutics; Combined Entity To Trade Under Ticker CLYD On Nasdaq
ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company
2025-10-24 23:05
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clin...
2025-10-24 23:00
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...
2025-10-17 11:58
